Phase 1/2 × OTHER × Carcinoma, Ovarian Epithelial × Clear all Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Phase 1/2 Recruiting
22 enrolled
NEODOC
Phase 1/2 Recruiting
10 enrolled
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
Phase 1/2 Recruiting
70 enrolled
OVHM-01
Phase 1/2 Terminated
9 enrolled
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Terminated
12 enrolled 8 charts
ORION-01
Phase 1/2 Terminated
13 enrolled
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 1/2 Completed
19 enrolled 12 charts
ORION-02
Phase 1/2 Unknown
31 enrolled
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Phase 1/2 Terminated
5 enrolled
Trientine
Phase 1/2 Completed
18 enrolled 16 charts
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Phase 1/2 Terminated
133 enrolled 10 charts
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 1/2 Terminated
15 enrolled 12 charts
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
Phase 1/2 Withdrawn
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
Phase 1/2 Completed
10 enrolled
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Phase 1/2 Completed
22 enrolled
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Phase 1/2 Unknown
50 enrolled
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Phase 1/2 Withdrawn
Chemotherapy in Treating Patients With Solid Tumors
Phase 1/2 Completed
57 enrolled
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
Phase 1/2 Completed
25 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Phase 1/2 Completed
11 enrolled
ETC
Phase 1/2 Terminated
3 enrolled
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Phase 1/2 Terminated
30 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer
Phase 1/2 Completed
15 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
Phase 1/2 Completed
50 enrolled
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Phase 1/2 Completed
30 enrolled
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1/2 Completed
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed